Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 2/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MAOB | P27338 | 3/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.33 |
| ▸ | PRKDC | P78527 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.33 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15619882 | 0.88 | PTGDR2 (0.46) | ERN1PTGDR2ALDH1A1CYP2A6PRKDC | |
| SCHEMBL15973528 | 0.87 | MAOA (0.37) | MAOBMAOA | |
| SCHEMBL15973530 | 0.87 | MAOA (0.37) | MAOBMAOA | |
| SCHEMBL16844646 | 0.78 | PYCR1 (0.34) | ALDH1A1PYCR1L3MBTL1 | |
| SCHEMBL4234831 | 0.78 | ALDH1A1 (0.47) | ERN1PTGDR2ALDH1A1HPGDLMNA | |
| SCHEMBL15989350 | 0.76 | MAOA (0.32) | MAOBMAOAPYCR1 | |
| SCHEMBL15972192 | 0.76 | MAOA (0.32) | MAOBMAOAPYCR1 | |
| SCHEMBL23111680 | 0.76 | PTGDR2 (0.46) | ERN1PTGDR2ALDH1A1MAOBMAOA | |
| SCHEMBL207935 | 0.76 | MAOA (0.52) | ERN1PTGDR2ALDH1A1MAOBMAOA | |
| SCHEMBL18532071 | 0.74 | RAB9A (0.38) | PTGDR2ALDH1A1PYCR1HPGDL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9708337-B2 | Aryl amide-based kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708337-B2 | Aryl amide-based kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708337-B2 | Aryl amide-based kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-18 | — | — | US | disclosed |
| EP-2958924-B1 | 5H-CHROMENO[3,4-C]PYRIDINES AS INHIBITORS OF ADAPTOR ASSOCIATED KINASE 1 (AAK1) | BRISTOL MYERS SQUIBB CO (US) | 2016-12-28 | — | — | EP | disclosed |
| US-20160016967-A1 | ARYL AMIDE-BASED KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-01-21 | — | — | US | disclosed |
| US-20160016967-A1 | ARYL AMIDE-BASED KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-01-21 | — | — | US | disclosed |
| US-20160016967-A1 | ARYL AMIDE-BASED KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-01-21 | — | — | US | disclosed |
| EP-2958924-A1 | 5H-CHROMENO[3,4-C]PYRIDINES AS INHIBITORS OF ADAPTOR ASSOCIATED KINASE 1 (AAK1) | Bristol-Myers Squibb Company (US) | 2015-12-30 | — | — | EP | disclosed |
| WO-2014130258-A1 | 5H-CHROMENO[3,4-C]PYRIDINES AS INHIBITORS OF ADAPTOR ASSOCIATED KINASE 1 (AAK1) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-28 | — | — | WO | disclosed |
| WO-2014130258-A1 | 5H-CHROMENO[3,4-C]PYRIDINES AS INHIBITORS OF ADAPTOR ASSOCIATED KINASE 1 (AAK1) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016967-A1 | ARYL AMIDE-BASED KINASE INHIBITORS | AAK1, ADCK1, NCK1 | ERN1 513/4885PTGDR2 3869/4885ALDH1A1 2933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.